Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an oral peptide targeting interleukin (IL)-23, a randomized study showed. The ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration ...

ORLANDO — A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy ...